Liver cancer experts attribute the rise in HCC, a highly aggressive cancer sometimes called hepatoma, to an increase decades ago in chronic infection with hepititis C & B and also chronic alcohol consumption. Worldwide liver cancer affects 700,000 people with 18,000 Americans diagnosed in 2006 and over 19,000 estimated to be diagnosed in 2007. The increase of this disease in the United States has doubled in one decade and over 16,000 people are estimated to die from the disease this year.

The rise in the United States is expected to increase. There are now 1.4 million people in the United States infected with HBV and 4 million are infected with HCV. Growing evidence suggests two other diseases now increasingly common in the United States to have significant risk factors for primary liver cancer. Diabetes and obesity.

HCC typically does not have any symptoms until its later stages which makes it difficult to diagnose. Traditional chemo does not treat the disease with much success and liver transplants or resection surgeries are needed. One reason why donors are very important in fighting this disease. When signs and symptoms do arise they might include weight loss, fatigue, pain in the upper right abdomen that may extend to the back and shoulder, feeling full after small meals, accumulation of fluid in the abdomen, nausea, loss of appetite, and jaundice.

Wouldn't it be great if we could find breast cancer long before something appears on a mammogram?

An FDA approved test called the Halo Breast Pap Test System might be able to do just that by collecting Nipple Aspirate Fluid (NAF). The test is designed to detect abnormal cells in the breast. The Halo system can identify benign disease as well as abnormal ductal cells that can be precursors to cancer.

Some research has suggested that ductal fluid excreted from the nipple can be used to identify a women's specific risk of breast cancer. A women with abnormal cells in the fluid has a four to five times greater risk of developing breast cancer.

Think about this:

The introduction of the HALO Breast Pap Test has been compared to the introduction of the Cervical Pap Test in the 1950s, which is widely credited with reducing cervical cancer death rates by more than 70 percent through the identification of abnormal cells in the cervix. Whether the same can be said for the breast pap test remains to be seen, but it is likely that the screen will be adopted by more OB-GYNs as oncologists push for ever earlier identification of cancer.

Tufts-New England Medical Center researchers are reporting that complications of seroma, the retaining of fluid in the breast, can occur from a procedure called brachytherapy. Brachytherapy is a breast cancer therapy performed during a lumpectomy that uses a catheter to insert a small balloon into the space where the tumor was removed and filling it with a radiation device that delivers high doses of radiation to the surrounding tissue. The complication that seems to be causing a problem is that a large number of breast cancer patients who undergo this procedure are developing fluid retention in the breast. Brachytherapy is used for a number of cancers, including prostate cancer. However, this report was specific to breast cancer patients.